Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
1998-1-2
pubmed:abstractText
Infants with acute lymphoblastic leukemia (ALL) have a very poor prognosis. Since 1985, we have intensified therapy for infants with ALL by including a month of high dose multiagent chemotherapy after remission induction.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/6-Mercaptopurine, http://linkedlifedata.com/resource/pubmed/chemical/Asparaginase, http://linkedlifedata.com/resource/pubmed/chemical/Core Binding Factor Alpha 2 Subunit, http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine, http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins, http://linkedlifedata.com/resource/pubmed/chemical/MLL protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate, http://linkedlifedata.com/resource/pubmed/chemical/Myeloid-Lymphoid Leukemia Protein, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion, http://linkedlifedata.com/resource/pubmed/chemical/TEL-AML1 fusion protein, http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
80
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2285-95
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9404706-6-Mercaptopurine, pubmed-meshheading:9404706-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9404706-Asparaginase, pubmed-meshheading:9404706-Core Binding Factor Alpha 2 Subunit, pubmed-meshheading:9404706-Cytarabine, pubmed-meshheading:9404706-DNA, Neoplasm, pubmed-meshheading:9404706-DNA-Binding Proteins, pubmed-meshheading:9404706-Disease-Free Survival, pubmed-meshheading:9404706-Female, pubmed-meshheading:9404706-Humans, pubmed-meshheading:9404706-Infant, pubmed-meshheading:9404706-Infant, Newborn, pubmed-meshheading:9404706-Male, pubmed-meshheading:9404706-Methotrexate, pubmed-meshheading:9404706-Myeloid-Lymphoid Leukemia Protein, pubmed-meshheading:9404706-Neoplasm Proteins, pubmed-meshheading:9404706-Oncogene Proteins, Fusion, pubmed-meshheading:9404706-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:9404706-Prognosis, pubmed-meshheading:9404706-Proto-Oncogenes, pubmed-meshheading:9404706-Remission Induction, pubmed-meshheading:9404706-Survival Rate, pubmed-meshheading:9404706-Transcription Factors, pubmed-meshheading:9404706-Treatment Outcome, pubmed-meshheading:9404706-Vincristine
pubmed:year
1997
pubmed:articleTitle
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
pubmed:affiliation
Children's Hospital, the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Multicenter Study